VC
SPRY icon

VarCov Co’s ARS Pharmaceuticals SPRY Stock Holding History

VarCov Co’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$264K Buy
32,945
+552
+2% +$4.75K 0.1% 302
2026
Q1 		$260K Buy
32,393
+10,093
+45% +$96.7K 0.1% 316
2025
Q4 		$260K Buy
+22,300
New +$217K 0.1% 343

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

VarCov Co's SPRY Position: Q2 2026 in Review

VarCov Co increased its ARS Pharmaceuticals (SPRY) stake by 1.7% in Q2 2026, buying an estimated $4.75K and bringing the position to 32,945 shares worth $264K. The position accounts for 0.1% of the portfolio, ranked #302.

VarCov Co first reported a position in SPRY in Q4 2025 and has held it in 3 quarters since. 204 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • VarCov Co held 32,945 shares of ARS Pharmaceuticals worth $264K as of Q2 2026.
  • VarCov Co bought 552 ARS Pharmaceuticals shares in Q2 2026, an estimated $4.75K.
  • ARS Pharmaceuticals made up 0.1% of VarCov Co's portfolio in Q2 2026, its #302 holding.
  • VarCov Co first reported a position in ARS Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 204 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on VarCov Co's 13F filing for Q2 2026, filed 14 Aug 2026.